Additionally, the study highlighted the importance of using predictive biomarkers to identify patients who will benefit most from this combination therapy and found that tumours with a mutational signature 3 (HRD signature) and a positive immune-score for exhausted CD8+ T cells were associated with an improved response (Färkkilä et al., 2020). The gene discussed is CD8A; the disease is neoplasm.